全文获取类型
收费全文 | 185篇 |
免费 | 6篇 |
专业分类
财政金融 | 26篇 |
工业经济 | 3篇 |
计划管理 | 25篇 |
经济学 | 61篇 |
综合类 | 2篇 |
运输经济 | 2篇 |
旅游经济 | 1篇 |
贸易经济 | 34篇 |
农业经济 | 17篇 |
经济概况 | 18篇 |
邮电经济 | 2篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 6篇 |
2019年 | 4篇 |
2018年 | 9篇 |
2017年 | 12篇 |
2016年 | 9篇 |
2015年 | 2篇 |
2014年 | 11篇 |
2013年 | 23篇 |
2012年 | 6篇 |
2011年 | 10篇 |
2010年 | 13篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 9篇 |
2006年 | 7篇 |
2005年 | 5篇 |
2004年 | 5篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 5篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1992年 | 2篇 |
1988年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有191条查询结果,搜索用时 0 毫秒
191.
Alexandre Gherardi Stéphane Roze Johan Kuijvenhoven Ola Ghatnekar Yum Lina Yip Sonderegger 《Journal of medical economics》2018,21(9):869-877
Aims: Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability with few adverse events. The aim of this study was to evaluate the cost-effectiveness of budesonide MMX versus commonly used corticosteroids, in the second-line treatment of active mild-to-moderate UC in the Netherlands.Materials and methods: An eight-state Markov model with an 8 week cycle length captured remission, four distinct therapy stages, hospitalization, possible colectomy and mortality. Remission probability for budesonide MMX was based on the CORE-II study. Population characteristics were derived from the Dutch Inflammatory Bowel Disease South Limburg cohort (n?=?598) and included patients with proctitis (39%), left-sided (42%) and extensive disease (19%). Comparators (topical budesonide foam and enema, oral budesonide and prednisolone) were selected based on current Dutch clinical practice. Treatment effects were evaluated by network meta-analysis using a Bayesian framework. Cost-effectiveness analysis was performed over a 5 year time horizon from a societal perspective, with costs, health-state and adverse event utilities derived from published sources. Outcomes were weighted by disease extent distribution and corresponding comparators.Results: Budesonide MMX was associated with comparable quality-adjusted life year (QALY) gain versus foam and oral formulations (+0.01 QALYs) in the total UC population, whilst being cost-saving (EUR 366 per patient). Probabilistic sensitivity analysis evaluated an 86.6% probability of budesonide MMX being dominant (cost-saving with QALY gain) versus these comparators. Exploratory analysis showed similar findings versus prednisolone.Limitations: Differing definitions of trial end-points and remission across trials meant indirect comparison was not ideal. However, in the absence of head-to-head clinical data, these comparisons are reasonable alternatives and currently offer the only comparison of second-line UC treatments.Conclusions: In the present analysis, budesonide MMX was shown to be cost-effective versus comparators in the total UC population, for the second-line treatment of active mild-to-moderate UC in the Netherlands. 相似文献